BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28653128)

  • 1. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    Chadha N; Jaggi AS; Silakari O
    Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
    Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
    Molecules; 2019 May; 24(10):. PubMed ID: 31108884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
    Kam CM; Tauber AL; Levonis SM; Schweiker SS
    Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
    Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
    Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
    Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold.
    Elmasry GF; Aly EE; Awadallah FM; El-Moghazy SM
    Bioorg Chem; 2019 Jun; 87():655-666. PubMed ID: 30952061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
    Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
    Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
    Zhou Y; Tang S; Chen T; Niu MM
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
    Zheng M; Mex M; Götz KH; Marx A
    Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
    Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
    J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
    J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach.
    Chadha N; Silakari O
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2324-2330. PubMed ID: 28438542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies Employed for the Development of PARP Inhibitors.
    Canan S; Maegley K; Curtin NJ
    Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
    Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
    Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
    Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
    Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
    Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
    Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
    Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
    Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
    Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.